Singapore’s Respiree closed $11.6 M Series A financing from We Venture Capital, ClavystBio
We Venture Capital and ClavystBio led a $11.6 million Series A financing round that was successfully closed by Respiree, a Singapore-based health tech company that produces artificial intelligence (AI) platforms to manage disease progression across the healthcare continuum.
Adaptive Capital Partners, the conversion of note securities from the Mayo Clinic’s Mayo Foundation for Medical Research, and previous investors Greenwillow Capital Management, Seeds Capital, and she1K angel investment also participated in the round, the company said in a statement on Wednesday.
The money raised will help Respiree grow its commercial team and presence in the United States, including the Texas Medical Center (TMC) Innovation in Houston, Texas, where the company’s headquarters are located.
Respiree, a Singaporean company, is currently implementing its global strategy to enter new markets across the globe.
The company’s products are presently offered in Asia-Pacific (APAC), Australia, and the United States.
The business and Roche Diagnostics recently announced their collaboration to start pilot projects throughout Asia Pacific (APAC).
In order to facilitate its growth in acute and home healthcare settings, the organization has also formed significant international alliances with top healthcare providers worldwide.
The Series A funds will be used in part to expedite the development of new business relationships and improve operations with current channel partners.
The Gulf Cooperation Council and Thailand are two more recent international markets where Respiree intends to broaden its product line.
“The digitalization of healthcare offers a powerful opportunity to improve outcomes and efficiency—but without the right tools, it risks overwhelming care systems, especially amid workforce shortages,” said Dr. Gurpreet Singh, Founder and Chief Executive Officer of Respiree.
“What we need is better use of data, not just more data. Our AI solutions enable timely interventions, reduce alarm fatigue, and support care quality,
“We’re now focused on scaling these tools to enhance the entire patient journey—from smarter triage to follow-up,” he added.
By automating patient monitoring, care pathway management, and clinical insight delivery, Respiree’s AI platform aims to facilitate faster, more accurate, and more efficient decision making in a variety of healthcare settings.
“Respiree stands out in the market by providing a patient monitoring AI/machine learning (ML) + hardware solution with incredible performance, but also unmatched understanding and execution of clinical workflow integration,
“Their scientifically validated data and key partnerships position Respiree for a promising scale-up journey driven by an extremely execution-focused team,” said Louise Warme, Head of We Venture Capital.
